In this study, Tumor IMmune Estimation Resource (TIMER) was used for ATAD2-associated pan-cancer analysis, which was followed by the analysis of ATAD2 expression and clinical relevance in Uterine Corpus Endometrial Carcinoma (UCEC) using various biochemical tools. The gene discussed is ATAD2; the disease is endometrial carcinoma.